The DAC system and associations with acute leukemias and myelodysplastic syndromes

Investigational New Drugs

Volumn 28, Issue SUPPL. 1, 2010, Pages

  Bug, Gesine ^a   Ottmann, Oliver G ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Acute myeloid leukemia; Deacetylase inhibitors; Drug development; Epigenetic therapy; Hypomethylating agents; Myelodysplastic syndromes; Targeted therapy

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; BELINOSTAT; CYTARABINE; DACINOSTAT; DNA METHYLTRANSFERASE; DOXORUBICIN; ENTINOSTAT; ETOPOSIDE; EVEROLIMUS; FLUDARABINE; GIVINOSTAT; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; METHOTREXATE; MIDOSTAURIN; MOCETINOSTAT; PANOBINOSTAT; RETINOIC ACID; ROMIDEPSIN; SALINOSPORAMIDE A; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL DIFFERENTIATION; CHEMOTHERAPY INDUCED EMESIS; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ELECTROCARDIOGRAM; FATIGUE; GASTROINTESTINAL TOXICITY; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC EPIGENESIS; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LEUKEMOGENESIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; ST SEGMENT DEPRESSION; T WAVE; THROMBOCYTOPENIA; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG SCREENING ASSAYS, ANTITUMOR; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; TRETINOIN;

EID: 78651356328     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-010-9595-z     Document Type: Article

References (103)

1. W Weichert 2009 HDAC expression and clinical prognosis in human malignancies Cancer Lett 280 2 168 176 1:CAS:528:DC%2BD1MXmsF2jt70%3D 10.1016/j.canlet.2008.10.047 19103471
2. R Redner J Wang J Liu 1999 Chromatin remodelling and leukemia: new therapeutic paradigms Blood 94 417 428 1:CAS:528:DyaK1MXksVemt7o%3D 10397708
3. LK Jones V Saha 2002 Chromatin modification, leukaemia and implications for therapy Br J Haematol 118 3 714 727 10.1046/j.1365-2141.2002.03586.x 12181038 (Pubitemid 35007375)
4. P Marks RA Rifkind VM Richon R Breslow T Miller WK Kelly 2001 Histone deacetylases and cancer: causes and therapies Nat Rev Cancer 1 3 194 202 1:CAS:528:DC%2BD38XlvF2qtr0%3D 10.1038/35106079 11902574
5. RW Johnstone JD Licht 2003 Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4 1 13 18 1:CAS:528:DC%2BD3sXmt1SltL0%3D 10.1016/S1535-6108(03)00165-X 12892709 (Pubitemid 36904157)
6. RK Lindemann B Gabrielli RW Johnstone 2004 Histone-deacetylase inhibitors for the treatment of cancer Cell Cycle 3 6 779 788 1:CAS:528: DC%2BD2MXmtVCmsQ%3D%3D 15153801
7. JM Scandura P Boccuni J Cammenga SD Nimer 2002 Transcription factor fusions in acute leukemia: variations on a theme Oncogene 21 21 3422 3444 1:CAS:528:DC%2BD38XksVWrsbY%3D 10.1038/sj.onc.1205315 12032780 (Pubitemid 34587714)
8. KL Durst SW Hiebert 2004 Role of RUNX family members in transcriptional repression and gene silencing Oncogene 23 24 4220 4224 1:CAS:528: DC%2BD2cXkvVChtrY%3D 10.1038/sj.onc.1207122 15156176 (Pubitemid 38758587)
9. CW So ML Cleary 2004 Dimerization: a versatile switch for oncogenesis Blood 104 4 919 922 1:CAS:528:DC%2BD2cXmslKgsr8%3D 10.1182/blood-2004-03-0992 15130940 (Pubitemid 39038008)
10. J Borrow VP Stanton Jr JM Andresen R Becher FG Behm RS Chaganti, et al. 1996 The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein Nat Genet 14 1 33 41 1:CAS:528:DyaK28Xls1Sqtb0%3D 10.1038/ng0996-33 8782817 (Pubitemid 26301544)
11. OM Sobulo J Borrow R Tomek S Reshmi A Harden B Schlegelberger, et al. 1997 MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3) Proc Natl Acad Sci USA 94 16 8732 8737 1:CAS:528:DyaK2sXltlWhsbs%3D 10.1073/pnas.94.16.8732 9238046 (Pubitemid 27335108)
12. B Linggi C Muller-Tidow L van de Locht M Hu J Nip H Serve, et al. 2002 The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia Nat Med 8 7 743 750 1:CAS:528:DC%2BD38XkvFehtrs%3D 10.1038/nm726 12091906 (Pubitemid 34778729)
13. U Krug A Ganser HP Koeffler 2002 Tumor suppressor genes in normal and malignant hematopoiesis Oncogene 21 21 3475 3495 1:CAS:528:DC%2BD38XksVWrtr8%3D 10.1038/sj.onc.1205322 12032783 (Pubitemid 34587717)
14. S Liu T Shen L Huynh MI Klisovic LJ Rush JL Ford, et al. 2005 Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia Cancer Res 65 4 1277 1284 1:CAS:528:DC%2BD2MXhsFKqtr8%3D 10.1158/0008-5472.CAN-04-4532 15735013 (Pubitemid 40270154)
15. XJ Yang M Ullah 2007 MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells Oncogene 26 37 5408 5419 1:CAS:528:DC%2BD2sXovFeku7k%3D 10.1038/sj.onc.1210609 17694082 (Pubitemid 47255923)
16. VI Rebel AL Kung EA Tanner H Yang RT Bronson DM Livingston 2002 Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal Proc Natl Acad Sci USA 99 23 14789 14794 1:CAS:528:DC%2BD38Xpt1yrtrw%3D 10.1073/pnas.232568499 12397173 (Pubitemid 35334562)
17. SA Gayther SJ Batley L Linger A Bannister K Thorpe SF Chin, et al. 2000 Mutations truncating the EP300 acetylase in human cancers Nat Genet 24 3 300 303 1:CAS:528:DC%2BD3cXhvFaqtL4%3D 10.1038/73536 10700188 (Pubitemid 30132203)
18. XJ Yang 2004 The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases Nucleic Acids Res 32 3 959 976 1:CAS:528:DC%2BD2cXhslWktLs%3D 10.1093/nar/gkh252 14960713 (Pubitemid 38864676)
19. GA Blobel 2000 CREB-binding protein and p300: molecular integrators of hematopoietic transcription Blood 95 3 745 755 1:CAS:528:DC%2BD3cXotV2jtA%3D%3D 10648382
20. JD Rowley S Reshmi O Sobulo T Musvee J Anastasi S Raimondi, et al. 1997 All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders Blood 90 2 535 541 1:CAS:528: DyaK2sXksF2jsb4%3D 9226152
21. CH Pui MV Relling JR Downing 2004 Acute lymphoblastic leukemia N Engl J Med 350 15 1535 1548 1:CAS:528:DC%2BD2cXjtVequrg%3D 10.1056/NEJMra023001 15071128 (Pubitemid 38477778)
22. A Zelent M Greaves T Enver 2004 Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia Oncogene 23 24 4275 4283 1:CAS:528:DC%2BD2cXkvVCht7g%3D 10.1038/sj.onc.1207672 15156184 (Pubitemid 38765136)
23. X Agirre A Vilas-Zornoza A Jimenez-Velasco JI Martin-Subero L Cordeu L Garate, et al. 2009 Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia Cancer Res 69 10 4443 4453 1:CAS:528:DC%2BD1MXlvFWluro%3D 10.1158/0008-5472.CAN-08-4025 19435910
24. D Marchion P Munster 2007 Development of histone deacetylase inhibitors for cancer treatment Expert Rev Anticancer Ther 7 4 583 598 1:CAS:528: DC%2BD2sXkt1Wqsrk%3D 10.1586/14737140.7.4.583 17428177 (Pubitemid 46690964)
25. M Dokmanovic PA Marks 2005 Prospects: histone deacetylase inhibitors J Cell Biochem 96 2 293 304 1:CAS:528:DC%2BD2MXhtFajurvM 10.1002/jcb.20532 16088937 (Pubitemid 41437862)
26. SG Gray CN Qian K Furge X Guo BT Teh 2004 Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines Int J Oncol 24 4 773 795 1:CAS:528:DC%2BD2cXjtlajurk%3D 15010814
27. MJ Peart GK Smyth RK van Laar DD Bowtell VM Richon PA Marks, et al. 2005 Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors Proc Natl Acad Sci USA 102 10 3697 3702 1:CAS:528:DC%2BD2MXisVOgsb0%3D 10.1073/pnas.0500369102 15738394 (Pubitemid 40354674)
28. KN Bhalla 2005 Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies J Clin Oncol 23 17 3971 3993 1:CAS:528: DC%2BD2MXmtVahtLg%3D 10.1200/JCO.2005.16.600 15897549 (Pubitemid 46218700)
29. SJ Haggarty KM Koeller JC Wong CM Grozinger SL Schreiber 2003 Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation Proc Natl Acad Sci USA 100 8 4389 4394 1:CAS:528:DC%2BD3sXjt12gtL0%3D 10.1073/pnas.0430973100 12677000 (Pubitemid 36457739)
30. D Wolf M Rodova EA Miska JP Calvet T Kouzarides 2002 Acetylation of beta-catenin by CREB-binding protein (CBP) J Biol Chem 277 28 25562 25567 1:CAS:528:DC%2BD38XlsVWhsb8%3D 10.1074/jbc.M201196200 11973335 (Pubitemid 34951872)
31. AJ Bannister EA Miska D Gorlich T Kouzarides 2000 Acetylation of importin-alpha nuclear import factors by CBP/p300 Curr Biol 10 8 467 470 1:CAS:528:DC%2BD3cXislyltLw%3D 10.1016/S0960-9822(00)00445-0 10801418 (Pubitemid 30247335)
32. G Blander N Zalle Y Daniely J Taplick MD Gray M Oren 2002 DNA damage-induced translocation of the Werner helicase is regulated by acetylation J Biol Chem 277 52 50934 50940 1:CAS:528:DC%2BD38Xps12nurg%3D 10.1074/jbc.M210479200 12384494 (Pubitemid 36042261)
33. HY Cohen S Lavu KJ Bitterman B Hekking TA Imahiyerobo C Miller, et al. 2004 Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis Mol Cell 13 5 627 638 1:CAS:528:DC%2BD2cXis1Kktbs%3D 10.1016/S1097-2765(04)00094-2 15023334 (Pubitemid 38368121)
34. L Fuino P Bali S Wittmann S Donapaty F Guo H Yamaguchi, et al. 2003 Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B Mol Cancer Ther 2 10 971 984 1:CAS:528:DC%2BD3sXosVCqt7g%3D 14578462
35. C Hubbert A Guardiola R Shao Y Kawaguchi A Ito A Nixon, et al. 2002 HDAC6 is a microtubule-associated deacetylase Nature 417 6887 455 458 1:CAS:528:DC%2BD38XjvVersr4%3D 10.1038/417455a 12024216 (Pubitemid 34563539)
36. Polevoda B, Sherman F (2002) The diversity of acetylated proteins. Genome Biol 3(5):reviews0006
37. S Minucci PG Pelicci 2006 Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat Rev Cancer 6 1 38 51 1:CAS:528:DC%2BD28Xht1GgsA%3D%3D 10.1038/nrc1779 16397526 (Pubitemid 43054973)
38. MA Glozak N Sengupta X Zhang E Seto 2005 Acetylation and deacetylation of non-histone proteins Gene 363 15 23 1:CAS:528:DC%2BD2MXht1Klu7%2FN 10.1016/j.gene.2005.09.010 16289629 (Pubitemid 41691888)
39. A Insinga S Monestiroli S Ronzoni V Gelmetti F Marchesi A Viale, et al. 2005 Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway Nature Med 11 1 71 76 1:CAS:528:DC%2BD2MXovF2m 10.1038/nm1160 15619634 (Pubitemid 40215840)
40. A Nebbioso N Clarke E Voltz E Germain C Ambrosino P Bontempo, et al. 2005 Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells Nature Med 11 1 77 84 1:CAS:528:DC%2BD2MXovF2l 10.1038/nm1161 15619633 (Pubitemid 40215841)
41. H Reikvam E Ersvaer O Bruserud 2009 Heat shock protein 90-a potential target in the treatment of human acute myelogenous leukemia Curr Cancer Drug Targets 9 6 761 776 1:CAS:528:DC%2BD1MXhtlKnurrJ 10.2174/156800909789271486 19754360
42. M Göttlicher S Minucci J Zhu O Krämer A Schimpf S Giavara, et al. 2001 Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells EMBO J 20 6969 6978 10.1093/emboj/20.24. 6969 11742974 (Pubitemid 34062289)
43. S Liu RB Klisovic T Vukosavljevic J Yu P Paschka L Huynh, et al. 2007 Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells J Pharmacol Exp Ther 321 3 953 960 1:CAS:528:DC%2BD2sXmsFeqsr8%3D 10.1124/jpet.106.118406 17389244 (Pubitemid 46762689)
44. G Bug K Schwarz C Schoch M Kampfmann R Henschler D Hoelzer, et al. 2007 Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia Haematologica 92 4 542 545 1:CAS:528:DC%2BD2sXhtFKrsrvE 10.3324/haematol.10758 17488665 (Pubitemid 350144299)
45. V Barbetti A Gozzini E Rovida A Morandi E Spinelli G Fossati, et al. 2008 Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells Oncogene 27 12 1767 1778 1:CAS:528: DC%2BD1cXjtFOnsLg%3D 10.1038/sj.onc.1210820 17891169 (Pubitemid 351380272)
46. M Murata M Towatari H Kosugi M Tanimoto R Ueda H Saito, et al. 2000 Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells Jpn J Cancer Res 91 11 1154 1160 1:CAS:528: DC%2BD3cXosVGrsLk%3D 11092981
47. A Romanski B Bacic G Bug H Pfeifer H Gul S Remiszewski, et al. 2004 Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia Haematologica 89 4 419 426 1:CAS:528: DC%2BD2cXot1Orurw%3D 15075075
48. A Scuto M Kirschbaum C Kowolik L Kretzner A Juhasz P Atadja, et al. 2008 The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph-acute lymphoblastic leukemia cells Blood 111 10 5093 5100 1:CAS:528:DC%2BD1cXmtlahsrY%3D 10.1182/blood-2007-10- 117762 18349321
49. M Tsapis M Lieb F Manzo P Shankaranarayanan R Herbrecht P Lutz, et al. 2007 HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway Int J Biochem Cell Biol 39 7-8 1500 1509 1:CAS:528: DC%2BD2sXnslWltbY%3D 10.1016/j.biocel.2007.03.009 17499001 (Pubitemid 47031039)
50. WA Stams ML den Boer HB Beverloo KM Kazemier ER van Wering GE Janka-Schaub, et al. 2005 Effect of the histone deacetylase inhibitor depsipeptide on B-cell differentiation in both TEL-AML1-positive and negative childhood acute lymphoblastic leukemia Haematologica 90 12 1697 1699 1:CAS:528:DC%2BD28XltVehsQ%3D%3D 16330447
51. HG Einsiedel L Kawan C Eckert O Witt I Fichtner G Henze, et al. 2006 Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia Leukemia 20 8 1435 1436 1:CAS:528:DC%2BD28XntVWksr8%3D 10.1038/sj.leu.2404282 16810202 (Pubitemid 44084058)
52. VM Richon Y Webb R Merger T Sheppard B Jursic L Ngo, et al. 1996 Second generation hybrid polar compounds are potent inducers of transformed cell differentiation Proc Natl Acad Sci USA 93 12 5705 5708 1:CAS:528: DyaK28Xjs1Kqtbc%3D 10.1073/pnas.93.12.5705 8650156 (Pubitemid 26191313)
53. SY Archer S Meng A Shei RA Hodin 1998 p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells Proc Natl Acad Sci USA 95 12 6791 6796 1:CAS:528:DyaK1cXjslynur8%3D 10.1073/pnas.95.12.6791 9618491 (Pubitemid 28278059)
54. LZ He T Tolentino P Grayson S Zhong RP Warrell Jr RA Rifkind, et al. 2001 Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia J Clin Investig 108 9 1321 1330 1:CAS:528:DC%2BD3MXot12kt7Y%3D 11696577
55. F Ferrara F Fazi A Bianchini F Padula V Gelmetti S Minucci, et al. 2001 Histone deacytylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia Cancer Res 61 2 7 11196162
56. EE Cameron KE Bachman S Myohanen JG Herman SB Baylin 1999 Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nat Genet 21 1 103 107 1:CAS:528:DyaK1MXltlWjtA%3D%3D 10.1038/5047 9916800 (Pubitemid 29036293)
57. JE Bolden MJ Peart RW Johnstone 2006 Anticancer activities of histone deacetylase inhibitors Nat reviews 5 9 769 784 1:CAS:528:DC%2BD28XptVCltrY%3D 10.1038/nrd2133 (Pubitemid 44348499)
58. C Fabre J Grosjean M Tailler S Boehrer L Ades JL Perfettini, et al. 2008 A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts Cell Cycle 7 14 2139 2145 1:CAS:528:DC%2BD1cXhtVykur3O 10.4161/cc.7.14.6268 18641459
59. W Fiskus K Buckley R Rao A Mandawat Y Yang R Joshi, et al. 2009 Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells Cancer Biol Ther 8 10 939 950 1:CAS:528:DC%2BD1MXpvFentbc%3D 19279403
60. Y Huang S Waxman 1998 Enhanced growth inhibition and differentiation of fluorodeoxyuridine-treated human colon carcinoma cells by phenylbutyrate Clin Cancer Res 4 10 2503 2509 1:CAS:528:DyaK1cXmvFykuro%3D 9796984
61. MS Kim M Blake JH Baek G Kohlhagen Y Pommier F Carrier 2003 Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA Cancer Res 63 21 7291 7300 1:CAS:528:DC%2BD3sXovVGlt70%3D 14612526
62. CS Mitsiades NS Mitsiades CJ McMullan V Poulaki R Shringarpure T Hideshima, et al. 2004 Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications Proc Natl Acad Sci USA 101 2 540 545 1:CAS:528:DC%2BD2cXmsFGnsA%3D%3D 10.1073/pnas. 2536759100 14695887 (Pubitemid 38084672)
63. TE Witzig M Timm M Stenson PA Svingen SH Kaufmann 2000 Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents Clin Cancer Res 6 2 681 692 1:CAS:528: DC%2BD3cXhs1akt7k%3D 10690554
64. DC Marchion E Bicaku AI Daud V Richon DM Sullivan PN Munster 2004 Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid J Cell Biochem 92 2 223 237 1:CAS:528:DC%2BD2cXjvVaqs7c%3D 10.1002/jcb.20045 15108350
65. EU Kurz SE Wilson KB Leader BP Sampey WP Allan JC Yalowich, et al. 2001 The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines Mol Cancer Ther 1 2 121 131 1:CAS:528:DC%2BD38XlsFSmtbY%3D 12467229
66. B Sanchez-Gonzalez H Yang C Bueso-Ramos K Hoshino A Quintas-Cardama VM Richon, et al. 2006 Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor Blood 108 4 1174 1182 1:CAS:528: DC%2BD28Xot1ymtLs%3D 10.1182/blood-2005-09-008086 16675713 (Pubitemid 44232012)
67. P Maiso E Colado EM Ocio M Garayoa J Martin P Atadja, et al. 2009 The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair Leukemia 23 12 2265 2274 1:CAS:528:DC%2BD1MXhsFKns7bJ 10.1038/leu.2009.182 19812608
68. K Shiozawa T Nakanishi M Tan HB Fang WC Wang MJ Edelman, et al. 2009 Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias Clin Cancer Res 15 5 1698 1707 1:CAS:528:DC%2BD1MXisVWrs78%3D 10.1158/1078-0432.CCR- 08-1587 19223502
69. SC Maggio RR Rosato LB Kramer Y Dai M Rahmani DS Paik, et al. 2004 The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells Cancer Res 64 7 2590 2600 1:CAS:528:DC%2BD2cXis1yju74%3D 10.1158/0008-5472.CAN-03-2631 15059916 (Pubitemid 38523917)
70. GJ Leclerc C Mou GM Leclerc AM Mian JC Barredo 2010 Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy Leukemia 24 3 552 562 1:CAS:528:DC%2BC3cXivFKgsLc%3D 10.1038/leu.2009.282 20072153
71. P Bali P George P Cohen J Tao F Guo C Sigua, et al. 2004 Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3 Clin Cancer Res 10 15 4991 4997 1:CAS:528:DC%2BD2cXmtlSitrs%3D 10.1158/1078-0432.CCR-04-0210 15297399 (Pubitemid 39099772)
72. C Nishioka T Ikezoe J Yang HP Koeffler A Yokoyama 2008 Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells Leukemia 22 12 2159 2168 1:CAS:528:DC%2BD1cXhsFWjtb7O 10.1038/leu.2008.243 18784743
73. B Kircher P Schumacher A Petzer E Hoflehner M Haun AM Wolf, et al. 2009 Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph + ALL and CML cells in vitro Eur J Haematol 83 1 48 56 1:CAS:528:DC%2BD1MXos1yiu7c%3D 10.1111/j.1600-0609.2009.01242.x 19226363
74. CP Miller K Ban ME Dujka DJ McConkey M Munsell M Palladino, et al. 2007 NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells Blood 110 1 267 277 1:CAS:528:DC%2BD2sXnsVaisbk%3D 10.1182/blood-2006-03-013128 17356134 (Pubitemid 47026844)
75. CP Miller S Rudra MJ Keating WG Wierda M Palladino J Chandra 2009 Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells Blood 113 18 4289 4299 1:CAS:528:DC%2BD1MXlvVGisbo%3D 10.1182/blood-2008-08-174797 19182209
76. Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, et al (2004) Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood. May 20
77. A Kuendgen S Knipp F Fox C Strupp B Hildebrandt C Steidl, et al. 2005 Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia Ann Hematol 84 Suppl 13 61 66 1:CAS:528:DC%2BD2MXht1OisrvE 10.1007/s00277-005-0026-8 16270213
78. A Kuendgen N Gattermann 2007 Valproic acid for the treatment of myeloid malignancies Cancer 110 5 943 954 1:CAS:528:DC%2BD2sXhtVChs7bE 10.1002/cncr.22891 17647267 (Pubitemid 47312858)
79. A Kuendgen M Schmid R Schlenk S Knipp B Hildebrandt C Steidl, et al. 2006 The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia Cancer 106 1 112 119 1:CAS:528:DC%2BD28XptF2ruw%3D%3D 10.1002/cncr.21552 16323176 (Pubitemid 43032555)
80. G Bug M Ritter B Wassmann C Schoch T Heinzel K Schwarz, et al. 2005 Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia Cancer 104 12 2717 2725 1:CAS:528: DC%2BD28XptlSktg%3D%3D 10.1002/cncr.21589 16294345 (Pubitemid 41798282)
81. G Cimino F Lo-Coco S Fenu L Travaglini E Finolezzi M Mancini, et al. 2006 Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia Cancer Res 66 17 8903 8911 1:CAS:528:DC%2BD28XovF2htLk%3D 10.1158/0008-5472.CAN-05-2726 16951208 (Pubitemid 44449209)
82. E Raffoux P Chaibi H Dombret L Degos 2005 Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia Haematologica 90 7 986 988 1:CAS:528:DC%2BD2MXot1Gjtrw%3D 15996941
83. G Garcia-Manero H Yang C Bueso-Ramos A Ferrajoli J Cortes WG Wierda, et al. 2008 Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes Blood 111 3 1060 1066 1:CAS:528:DC%2BD1cXhvFejsb8%3D 10.1182/blood-2007-06-098061 17962510 (Pubitemid 351213383)
84. EW Schaefer A Loaiza-Bonilla M Juckett JF DiPersio V Roy J Slack, et al. 2009 A phase 2 study of vorinostat in acute myeloid leukemia Haematologica 94 10 1375 1382 1:CAS:528:DC%2BD1MXhsVCrsrnI 10.3324/haematol.2009.009217 19794082
85. F Giles T Fischer J Cortes G Garcia-Manero J Beck F Ravandi, et al. 2006 A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies Clin Cancer Res 12 15 4628 4635 1:CAS:528:DC%2BD28XnvVGks7s%3D 10.1158/1078-0432.CCR-06-0511 16899611 (Pubitemid 44297814)
86. O Ottmann A Spencer H Prince K Bhalla T Fischer A Liu, et al. 2008 Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies Blood 112 a958
87. OM Odenike S Alkan D Sher JE Godwin D Huo SJ Brandt, et al. 2008 Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia Clin Cancer Res 14 21 7095 7101 1:CAS:528:DC%2BD1cXhtlens7fF 10.1158/1078-0432.CCR-08-1007 18981008
88. VM Klimek S Fircanis P Maslak I Guernah M Baum N Wu, et al. 2008 Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes Clin Cancer Res 14 3 826 832 1:CAS:528: DC%2BD1cXhsFykt7Y%3D 10.1158/1078-0432.CCR-07-0318 18245545 (Pubitemid 351231166)
89. P Gimsing M Hansen LM Knudsen P Knoblauch IJ Christensen CE Ooi, et al. 2008 A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia Eur J Haematol 81 3 170 176 1:CAS:528:DC%2BD1cXhtFentLzK 10.1111/j.1600-0609.2008.01102.x 18510700
90. G Garcia-Manero S Assouline J Cortes Z Estrov H Kantarjian H Yang, et al. 2008 Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia Blood 112 4 981 989 1:CAS:528:DC%2BD1cXpvVOksL4%3D 10.1182/blood-2007-10-115873 18495956
91. I Gojo A Jiemjit JB Trepel A Sparreboom WD Figg S Rollins, et al. 2007 Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias Blood 109 7 2781 2790 1:CAS:528:DC%2BD2sXjvVynsrY%3D 17179232
92. RL Piekarz AR Frye JJ Wright SM Steinberg DJ Liewehr DR Rosing, et al. 2006 Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma Clin Cancer Res 12 12 3762 3773 1:CAS:528: DC%2BD28XlvVSltr8%3D 10.1158/1078-0432.CCR-05-2095 16778104 (Pubitemid 44000258)
93. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, et al (2006) Phase I/II study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood. Aug 1
94. W Blum RB Klisovic B Hackanson Z Liu S Liu H Devine, et al. 2007 Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia J Clin Oncol 25 25 3884 3891 1:CAS:528:DC%2BD2sXhtFanu7zF 10.1200/JCO.2006.09.4169 17679729 (Pubitemid 47477265)
95. AO Soriano H Yang S Faderl Z Estrov F Giles F Ravandi, et al. 2007 Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome Blood 110 7 2302 2308 1:CAS:528:DC%2BD2sXhtFCnsbzJ 10.1182/blood-2007-03-078576 17596541 (Pubitemid 47523148)
96. MT Voso V Santini C Finelli P Musto E Pogliani E Angelucci, et al. 2009 Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes Clin Cancer Res 15 15 5002 5007 1:CAS:528:DC%2BD1MXptl2gtrg%3D 10.1158/1078-0432.CCR-09-0494 19638460
97. SD Gore S Baylin E Sugar H Carraway CB Miller M Carducci, et al. 2006 Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms Cancer Res 66 12 6361 6369 1:CAS:528: DC%2BD28XlvVSkurc%3D 10.1158/0008-5472.CAN-06-0080 16778214
98. M Kirschbaum I Gojo S Goldberg L Kujawski E Atallah PA Marks, et al. 2009 Vorinostat in combination with decitabine for the treatment of relapsed or newly diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): a phase i, dose-escalation study Blood 114 2089a
99. T Kadia Z Estrov F Ravandi C Koller G Borthakur E Jabbour, et al. 2009 Long term followup and patterns of failure in patients with Acute Myeloid Leukemia (AML) and high risk Myelodysplastic Syndrome (MDS) treated on studies combining a hypomethylating agent and the histone deacetylase inhibitor (HDACi) valproic acid Blood 114 2074a
100. Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, et al (2010) A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol. Apr 29
101. G Garcia-Manero F Tambaro B Bekele E Jabbour F Ravandi H Yang, et al. 2009 Phase II study of vorinostat in combination with idarubicin (Ida) and cytarabine (ara-C) as front line therapy in Acute Myelogenous Leukemia (AML) or higher risk myelodysplastic syndrome (MDS) Blood 114 1055a
102. S Hauswald J Duque-Afonso MM Wagner FM Schertl M Lubbert C Peschel, et al. 2009 Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes Clin Cancer Res 15 11 3705 3715 1:CAS:528:DC%2BD1MXmsFOjtbg%3D 10.1158/1078-0432.CCR-08-2048 19458058
103. Y Tabe M Konopleva R Contractor M Munsell WD Schober L Jin, et al. 2006 Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells Blood 107 4 1546 1554 1:CAS:528:DC%2BD28XhsFemt7o%3D 10.1182/blood-2004-10-4126 16223781 (Pubitemid 43242393)